Baker BROS. Advisors LP Purchases 832,432 Shares of Immatics (NASDAQ:IMTX)

Baker BROS. Advisors LP boosted its holdings in Immatics (NASDAQ:IMTX - Free Report) by 12.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,275,830 shares of the company's stock after acquiring an additional 832,432 shares during the quarter. Immatics comprises about 0.6% of Baker BROS. Advisors LP's investment portfolio, making the stock its 22nd biggest holding. Baker BROS. Advisors LP owned 6.10% of Immatics worth $51,731,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Bank of America Corp DE lifted its stake in Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after purchasing an additional 2,231 shares during the last quarter. Algert Global LLC lifted its position in shares of Immatics by 173.1% during the 4th quarter. Algert Global LLC now owns 58,596 shares of the company's stock valued at $417,000 after acquiring an additional 37,138 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Immatics by 31.5% during the 4th quarter. Northern Trust Corp now owns 47,226 shares of the company's stock worth $336,000 after acquiring an additional 11,304 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after acquiring an additional 2,479 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its position in shares of Immatics by 43.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company's stock worth $75,400,000 after purchasing an additional 3,225,141 shares during the period. 64.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $16.67.

Immatics Stock Performance

Shares of IMTX stock traded down $0.09 on Friday, reaching $4.25. 390,723 shares of the company's stock traded hands, compared to its average volume of 658,679. The company has a market capitalization of $516.59 million, a P/E ratio of -6.44 and a beta of 0.87. Immatics has a 12-month low of $3.30 and a 12-month high of $13.77. The business's 50 day moving average price is $4.48 and its two-hundred day moving average price is $6.07.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.51. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The company had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million. Research analysts predict that Immatics will post -0.72 earnings per share for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.